

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934  
(Amendment No. )\*

**NGM Biopharmaceuticals Inc.**

---

(Name of Issuer)

**Common Stock**

---

(Title of Class of Securities)

**62921N 10 5**

---

(CUSIP Number)

**April 8, 2019**

---

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

- Rule 13d-1(b)
- Rule 13d-1(c)
- Rule 13d-1(d)

\*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

---

SCHEDULE 13G

CUSIP No. 62921N 10 5

1 Names of Reporting Persons  
Merck & Co., Inc.

2 Check the Appropriate Box if a Member of a Group (See Instructions)

(a)

(b)

3 SEC Use Only

4 Citizenship or Place of Organization  
New Jersey

5 Sole Voting Power  
12,955,016

Number of  
Shares  
Beneficially  
Owned by  
Each  
Reporting  
Person With:

6 Shared Voting Power  
0

7 Sole Dispositive Power  
12,955,016

8 Shared Dispositive Power  
0

9 Aggregate Amount Beneficially Owned by Each Reporting Person  
12,955,016

10 Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

11 Percent of Class Represented by Amount in Row (9)  
19.9%

12 Type of Reporting Person (See Instructions)  
HC

\* Based on 65,098,913 shares of the Issuer's common stock outstanding immediately following the Issuer's public offering, which includes the full exercise of the underwriters' over-allotment option, as reported in the Issuer's Prospectus filed pursuant to Rule 424(b)(4) with the Securities and Exchange Commission on April 4, 2019, which is part of the Issuer's Registration Statement.

1 Names of Reporting Persons  
Merck Sharp & Dohme Corp.

---

2 Check the Appropriate Box if a Member of a Group (See Instructions)

(a)  0

(b)  0

---

3 SEC Use Only

---

4 Citizenship or Place of Organization  
New Jersey

---

5 Sole Voting Power  
12,955,016

---

Number of  
Shares  
Beneficially  
Owned by  
Each  
Reporting  
Person With:

6 Shared Voting Power  
0

---

7 Sole Dispositive Power  
12,955,016

---

8 Shared Dispositive Power  
0

---

9 Aggregate Amount Beneficially Owned by Each Reporting Person  
12,955,016

---

10 Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

---

11 Percent of Class Represented by Amount in Row (9)  
19.9%

---

12 Type of Reporting Person (See Instructions)  
CO

---

\* Based on 65,098,913 shares of the Issuer's common stock outstanding immediately following the Issuer's public offering, which includes the full exercise of the underwriters' over-allotment option, as reported in the Issuer's Prospectus filed pursuant to Rule 424(b)(4) with the Securities and Exchange Commission on April 4, 2019, which is part of the Issuer's Registration Statement.

**Item 1.**

- (a) Name of Issuer:  
NGM Biopharmaceuticals Inc.
- 
- (b) Address of Issuer's Principal Executive Offices:  
333 Oyster Point Boulevard, South San Francisco, California 94080
- 

**Item 2.**

- (a) Name of Person Filing:  
(1) Merck & Co., Inc.  
(2) Merck Sharp & Dohme Corp.
- 
- (b) Address of Principal Business Office or, if none, Residence:  
(1) Merck & Co., Inc.: 2000 Galloping Hill Road, Kenilworth, NJ 07033  
(2) Merck Sharp & Dohme Corp.: One Merck Drive, Whitehouse Station, NJ 08889
- 
- (c) Citizenship:  
(1) Merck & Co., Inc.: New Jersey  
(2) Merck Sharp & Dohme Corp.: New Jersey
- 
- (d) Title and Class of Securities:  
Common Stock
- 
- (e) CUSIP No.:  
62921N 10 5
- 

**Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:**

- (a)  Broker or dealer registered under section 15 of the Act;
- (b)  Bank as defined in section 3(a)(6) of the Act;
- (c)  Insurance company as defined in section 3(a)(19) of the Act;
- (d)  Investment company registered under section 8 of the Investment Company Act of 1940;
- (e)  An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
- (f)  An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);
- (g)  A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);
- (h)  A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
- (i)  A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940;
- (j)  A non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J);
- (k)  Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J), please specify the type of institution: \_\_\_\_\_

**Item 4. Ownership**

Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

- (a) Amount beneficially owned:

12,955,016

The reported securities are owned directly by Merck Sharp & Dohme Corp. (“MSD”), which is a wholly owned subsidiary of Merck & Co., Inc. (“Merck”). MSD and Merck are indirect beneficial owners of the reported securities.

---

- (b) Percent of class:

19.9%

---

- (c) Number of shares as to which such person has:
- 

- (i) Sole power to vote or to direct the vote:

See Cover Pages Items 5-9.

---

- (ii) Shared power to vote or to direct the vote:

See Cover Pages Items 5-9.

---

- (iii) Sole power to dispose or to direct the disposition of :

See Cover Pages Items 5-9.

---

- (iv) Shared power to dispose or to direct the disposition of:

See Cover Pages Items 5-9.

---

**Item 5. Ownership of Five Percent or Less of a Class.**

Not Applicable.

**Item 6. Ownership of More than Five Percent on Behalf of Another Person.**

Not Applicable.

**Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.**

The reported securities are owned directly by MSD, which is a wholly owned subsidiary of Merck. MSD and Merck are indirect beneficial owners of the reported securities.

**Item 8. Identification and Classification of Members of the Group.**

Not Applicable.

**Item 9. Notice of Dissolution of Group.**

Not Applicable.

**Item 10. Certifications.**

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

**SIGNATURE**

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: April 9, 2019

**MERCK SHARP & DOHME CORP.**

By: /s/ Faye C. Brown  
Name: Faye C. Brown  
Title: Assistant Secretary

**MERCK & CO., INC.**

By: /s/ Faye C. Brown  
Name: Faye C. Brown  
Title: Senior Assistant Secretary